REFERENCES
- TB: A Global Emergency. WHO Report on the TB Epidemic, Tuberculosis Programme; World Health Organization: Geneva, 1994; , WHO/TB/94.177.
- IUATLD/WHO. The promise and reality of fixed-dose combinations with rifampicin. A joint statement of International Union Against Tuberculosis and Lung Diseases and the Tuberculosis Programme of the World Health Organization.Tuber. Lung Dis. 1994, 75, 180–181., [CSA]
- Fox, W. Drug combinations and bioavailability of rifampicin.Tubercle 1990, 71, 241–243., [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Laserson, K.F.; Kenyon, A.S.; Kenyon, T.A.; Layloff, T.; Binkin, N.J. Substandard tuberculosis drugs on the global market and their simple detection.Int. J. Tuberc. Lung Dis. 2001, 5, 448–454., [PUBMED], [INFOTRIEVE], [CSA]
- http://www.who.int/medicines/organization/par/FDC/FDCmain.shtml , (accessed September 2004).
- Singh, S.; Mariappan, T.T.; Sharda, N.; Singh, B. Degradation of rifampicin, isoniazid and pyrazinamide from prepared mixtures and marketed single and combination products under acid conditions.Pharm. Pharmacol. Commun. 2000, 6, 491–494., [CSA]
- Singh, S.; Mariappan, T.T.; Sharda, N.; Kumar, S.; Chakraborti, A.K. The reason for an increase in decomposition of rifampicin in the presence of isoniazid under acid conditions.Pharm. Pharmacol. Commun. 2000, 6, 405–410., [CSA]
- Singh, S.; Mariappan, T.T.; Sankar, R.; Sarda, N.; Singh, B. A critical review of the probable reasons for the poor/variable bioavailability of rifampicin from anti-tubercular fixed-dose combination (FDC) products, and the likely solutions to the problem.Int. J. Pharm. 2001, 228, 5–17., [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Sankar, R.; Sharda, N.; Singh, S. Behaviour of decomposition of rifampicin in the presence of isoniazid in the pH range 1–3.Drug Dev. Ind. Pharm. 2003, 29, 733–738., [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Singh, S.; Mohan, B. A pilot stability study on anti-tuberculosis four drug fixed dose combination products.Int. J. Tuberc. Lung Dis. 2003, 7, 298–303., [PUBMED], [INFOTRIEVE], [CSA]
- Bhutani, H.; Mariappan, T.T.; Singh, S. The physical and chemical stability of anti-tuberculosis fixed-dose combination (FDC) products under accelerated climatic conditions.Int. J. Tuberc. Lung Dis. 2004, 8, 1073–1080., [PUBMED], [INFOTRIEVE], [CSA]
- Bhutani, H.; Mariappan, T.T.; Singh, S. An explanation for the physical instability of a marketed fixed dose combination (FDC) formulation containing isoniazid and ethambutol and the proposed solutions.Drug Dev. Ind. Pharm. 2004, 30, 667–672., [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Mohan, B.; Sharda, N.; Singh, S. Evaluation of recently reported USP gradient method for anti-tuberculosis drugs in FDCs for its ability to resolve degradation products of rifampicin.J. Pharm. Biomed. Anal. 2003, 31, 607–612., [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Mariappan, T.T.; Singh, S.; Pandey, R.; Sharma, A. Isonicotinyl hydrazone of rifampicin and isoniazid: should it be controlled as a related substance (or impurity) in USP monographs for anti-tuberculosis combination products?Pharmacop. Forum 2005, 31, 646–652.
- The International Pharmacopoeia: monograph for tuberculosis medicines—Rifampicin, isoniazid, pyrazinamide and ethambutol hydrochloride tablets (1st draft). WHO Drug Information 2004, 18 (4), 313–317., [CSA]
- Conte, J.E.; Lin, E.; Zhao, Y.; Zurlinden, E. A high-pressure liquid chromatographic-tandem mass spectrometric method for the determination of ethambutol in human plasma, bronchoalveolar lavage fluid, and alveolar cells.J. Chromatogr. Sci. 2002, 40, 113–118., [PUBMED], [INFOTRIEVE], [CSA]
- Bhutani, H.; Singh, S; Jindal, K.C.; Chakraborti, A.K. Mechanistic explanation to the catalysis by pyrazinamide and ethambutol of reaction between rifampicin and isoniazid in anti-TB FDCs. J. Pharm. Biomed. Anal. 2005, 39, 892–899., [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]